Open-Angle Glaucoma

Overview

Open-angle glaucoma represents a group of optic neuropathies characterized by progressive loss of retinal ganglion cells and their axons, resulting in characteristic optic nerve head changes and corresponding visual field defects. The anterior chamber angle remains open on gonioscopy, distinguishing it from angle-closure glaucoma. Primary open-angle glaucoma is the most common variant, though the category also includes normal-tension glaucoma (where damage occurs despite statistically normal IOP) and secondary forms such as pseudoexfoliative glaucoma.¹ The condition typically progresses insidiously, and early detection combined with IOP-lowering treatment is essential to preserve vision.

Epidemiology & Risk Factors

Open-angle glaucoma is among the most prevalent causes of irreversible blindness worldwide. Multiple risk factors contribute to disease development and progression:

• Elevated intraocular pressure: The primary modifiable risk factor
• Age: Prevalence increases with advancing age
• Vascular factors: May play a role in disease pathogenesis²
• Genetic predisposition: Family history increases risk
• Structural factors: Baseline optic nerve morphology and corneal characteristics
• Systemic associations: Relationships with conditions such as diabetes mellitus have been described³

The GLAUrious trial enrolled participants aged 40 years or older, reflecting the typical age range for diagnosis and treatment.⁴

Pathophysiology

The etiopathogenesis of primary open-angle glaucoma remains complex and incompletely understood. Several theories have been proposed to explain the mechanisms underlying glaucomatous optic neuropathy²:

• Mechanical (retentional/hydromechanical) theory: Elevated IOP causes mechanical stress on retinal ganglion cell axons at the lamina cribrosa, leading to axonal damage and cell death
• Vascular theory: Compromised blood flow to the optic nerve head contributes to ischemic injury of retinal ganglion cells
• Dystrophic theory: Primary scleropathy and extracellular matrix changes in the trabecular meshwork and lamina cribrosa
• Metabolic theory: Metabolic dysfunction and oxidative stress contribute to neurodegeneration
• Individual IOP norm concept: Damage occurs when IOP exceeds the tolerance threshold specific to each individual's optic nerve
• Liquor hypertension concept: Cerebrospinal fluid pressure dynamics may influence the pressure gradient across the lamina cribrosa

These mechanisms likely interact, with individual variation in susceptibility explaining why some patients develop damage at lower IOP levels while others tolerate higher pressures without progression.

Clinical Presentation

Open-angle glaucoma typically presents insidiously without early symptoms, making it a diagnostic challenge:

• Early disease: Usually asymptomatic; detected during routine eye examinations
• Intermediate disease: Gradual peripheral visual field loss that patients often do not notice due to binocular compensation and the brain's ability to fill in scotomas
• Advanced disease: Patients may report difficulty with mobility, reading (when central vision is affected), or noticing objects in the periphery
• End-stage disease: Severe constriction of visual fields or central vision loss affecting activities of daily living

The lack of pain or acute symptoms in open-angle glaucoma contrasts sharply with angle-closure glaucoma and contributes to delayed diagnosis in many cases. Patients with ocular hypertension (elevated IOP without detectable optic nerve damage or visual field loss) are asymptomatic but at increased risk for developing glaucoma.

Exam Findings

Comprehensive ophthalmic examination is essential for diagnosis and monitoring:

• Intraocular pressure: Elevated IOP (traditionally >21 mmHg), though damage can occur at any pressure level; normal-tension glaucoma demonstrates progressive damage despite IOP in the statistically normal range
• Gonioscopy: Open anterior chamber angle distinguishes open-angle from angle-closure mechanisms; may reveal pigment deposition or pseudoexfoliative material in secondary forms
• Optic nerve head assessment:
  • Increased cup-to-disc ratio
  • Asymmetry between eyes
  • Neuroretinal rim thinning or notching, especially inferotemporal and superotemporal
  • Disc hemorrhages (Drance hemorrhages)
  • Peripapillary atrophy
  • Nerve fiber layer defects
• Visual field testing: Characteristic patterns including nasal steps, arcuate scotomas, and paracentral defects; advanced disease shows generalized constriction
• Optical coherence tomography (OCT): Quantifies retinal nerve fiber layer and ganglion cell layer thickness; helpful for early detection and progression monitoring
• Central corneal thickness: Thinner corneas may be associated with underestimation of true IOP

Classification

Open-angle glaucoma encompasses several distinct entities:

• Primary open-angle glaucoma (POAG): Most common form; elevated IOP with characteristic optic nerve damage and visual field loss without identifiable secondary cause
• Normal-tension glaucoma (NTG): Glaucomatous optic neuropathy and visual field defects despite IOP consistently in the statistically normal range (≤21 mmHg)
• Pseudoexfoliative glaucoma: Secondary open-angle glaucoma associated with deposition of fibrillar extracellular material in the anterior segment; typically more aggressive with higher IOP levels¹
• Pigmentary glaucoma: Secondary form caused by pigment dispersion from posterior iris surface, leading to trabecular meshwork obstruction⁴
• Ocular hypertension (OHT): Elevated IOP without detectable optic nerve damage or visual field loss; represents a risk state for developing glaucoma

Each subtype has distinct pathophysiologic features and may differ in treatment response and prognosis.

Differential Diagnosis

• Ocular hypertension: Elevated IOP without optic nerve damage or visual field defects
• Physiologic optic disc cupping: Large cups without progressive change or visual field loss
• Other optic neuropathies: Ischemic optic neuropathy, compressive lesions, hereditary optic neuropathies
• Neurologic visual field defects: Stroke, intracranial masses causing homonymous or bitemporal field loss
• Retinal disease: Retinal detachment, advanced macular degeneration, or vascular occlusions causing field defects
• Artifact or unreliable testing: Poor fixation, ptosis, or refractive error causing apparent field defects
• Angle-closure glaucoma: Distinguished by narrow or closed anterior chamber angle on gonioscopy
• Congenital glaucoma: Presents in infancy or early childhood with enlarged globe, corneal edema

Management

The primary goal of treatment is to lower IOP to a level that slows or halts progression of optic nerve damage and visual field loss. Management follows a stepwise approach:

Initial Treatment Options

Medical Therapy
Traditionally the first-line approach, topical IOP-lowering medications include prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, and cholinergic agents. These may be used individually or in combination to achieve target IOP.

Selective Laser Trabeculoplasty (SLT)
The LiGHT trial demonstrated that initial treatment with SLT is clinically and cost-effective compared to IOP-lowering eye drops. At 6 years, 69.8% of eyes in the SLT arm of the LiGHT trial remained at or below target IOP without need for medical or surgical treatment.⁵ This trial enrolled treatment-naive eyes with OAG or ocular hypertension with untreated or washed-out IOP of 22-35 mmHg.⁵ SLT can be repeated if the initial effect wanes; the LiGHT trial protocol allowed a third SLT if necessary after the initial 3-year period.⁵

Direct Selective Laser Trabeculoplasty (DSLT)
The GLAUrious trial is evaluating a newer translimbal DSLT device (Eagle) designed to provide automated, fast, and simple laser treatment. This trial enrolled participants aged 40 years or older with OAG (including exfoliative or pigmentary glaucoma) or ocular hypertension with untreated or washed-out IOP of 22-35 mmHg.⁴ The DSLT protocol uses 120 shots over 2 seconds delivered at the limbus.⁴

Treatment Escalation

• Additional topical medications if monotherapy insufficient
• Laser trabeculoplasty if not used initially or repeat laser if prior response
• Incisional glaucoma surgery (trabeculectomy, tube shunt) for inadequate control

In the LiGHT trial, trabeculectomy was required in 13 eyes in the SLT arm compared with 32 eyes in the drops arm over 6 years.⁵

Target IOP and Monitoring

Target IOP is individualized based on severity of damage at presentation, rate of progression, and life expectancy. Regular monitoring includes IOP measurement, optic nerve assessment, and visual field testing to detect progression and adjust treatment accordingly.¹

Complications

Disease-Related Complications

• Progressive visual field loss: Despite treatment, some patients continue to lose visual function
• Irreversible blindness: Advanced glaucoma can result in severe visual impairment or legal blindness
• Reduced quality of life: Visual impairment affects mobility, driving, reading, and independence

Treatment-Related Complications

Medical Therapy

• Ocular surface disease and discomfort from preservatives
• Systemic side effects (beta-blockers: bradycardia, bronchospasm; carbonic anhydrase inhibitors: fatigue, paresthesias)
• Hyperemia, eyelash changes, periocular pigmentation (prostaglandin analogs)
• Poor adherence due to complexity of regimens or side effects

Laser Trabeculoplasty The LiGHT trial reported no serious laser-related adverse events over 6 years.⁵ Transient IOP elevation and mild inflammation are typically managed with observation or short-term medication.

Incisional Surgery

• Hypotony with potential choroidal effusion or maculopathy
• Infection (endophthalmitis, bleb-related infections)
• Cataract formation: More cataract surgeries occurred in the drops arm of the LiGHT trial (95 eyes) compared with the SLT arm (57 eyes) over 6 years.⁵
• Bleb-related complications (leaks, encapsulation, dysesthesia)
• Vision loss from surgical complications

Clinical Pearls

• Open-angle glaucoma is typically asymptomatic until advanced, emphasizing the importance of routine screening, particularly in at-risk populations
• Normal IOP does not exclude glaucoma; normal-tension glaucoma accounts for a significant proportion of cases
• In the LiGHT trial, eyes initially treated with SLT showed less disease progression (19.6%) compared with those treated with drops (26.8%) over 6 years.⁵
• Selective laser trabeculoplasty has demonstrated better long-term disease control than initial drop therapy, with reduced need for incisional glaucoma surgery and cataract surgery over 6 years.⁵
• At 6 years in the LiGHT trial, the SLT arm showed better Glaucoma Symptom Scale scores compared with the drops arm.⁵
• Adherence to medical therapy is a major challenge; laser trabeculoplasty eliminates the need for daily eye drops in many patients
• Asymmetry between eyes in cup-to-disc ratio, rim appearance, or IOP should raise suspicion for glaucoma
• Optic disc hemorrhages are a sign of active glaucomatous damage and often herald progression
• The etiopathogenesis of POAG involves multiple interacting theories including mechanical, vascular, dystrophic, and metabolic mechanisms.²

Common Pitfalls

• Relying solely on IOP: Elevated IOP is not required for diagnosis; glaucomatous damage can occur at any pressure level
• Missing normal-tension glaucoma: Assuming normal IOP excludes glaucoma leads to delayed diagnosis and treatment
• Inadequate gonioscopy: Failing to perform careful angle examination may miss angle-closure mechanisms or secondary causes
• Ignoring progression: Assuming stable IOP means stable disease; regular visual field and optic nerve assessments are essential
• Underestimating adherence issues: Not addressing patient difficulties with drop administration or medication side effects
• Setting overly conservative targets: In advanced disease or rapidly progressing cases, aggressive IOP lowering may be necessary
• Delaying surgical intervention: Waiting too long to proceed with incisional surgery when medical and laser treatments are inadequate
• Overlooking binocular status: Focusing on the worse eye while neglecting earlier disease in the fellow eye
• Misinterpreting trial eligibility criteria as diagnostic thresholds: For example, the LiGHT and GLAUrious trials enrolled patients with specific IOP ranges for study purposes, not as diagnostic criteria for all open-angle glaucoma.^5,4
• Failing to consider laser as first-line therapy: Given evidence from the LiGHT trial supporting SLT as initial treatment, defaulting exclusively to medical therapy may not represent optimal care for all patients